These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 20368718

  • 1. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.
    Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH.
    Pharmacogenomics J; 2011 Jun; 11(3):237-46. PubMed ID: 20368718
    [Abstract] [Full Text] [Related]

  • 2. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 3. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 4. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W.
    Transplant Proc; 2005 Jun; 37(1):178-81. PubMed ID: 15808586
    [Abstract] [Full Text] [Related]

  • 5. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P.
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 7. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK.
    Transplantation; 2003 Oct 27; 76(8):1233-5. PubMed ID: 14578760
    [Abstract] [Full Text] [Related]

  • 8. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL, Xie HG, Yao Y, Hu YF.
    Pharmacogenet Genomics; 2011 Nov 27; 21(11):713-20. PubMed ID: 21886016
    [Abstract] [Full Text] [Related]

  • 9. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J, Kim MG, Choi B, Han NY, Yun HY, Yoon JH, Oh JM.
    Ann Pharmacother; 2012 Sep 27; 46(9):1141-51. PubMed ID: 22947591
    [Abstract] [Full Text] [Related]

  • 10. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P, Li J, Li J, Deng R, Fu Q, Chen J, Huang M, Chen X, Wang C.
    J Clin Pharm Ther; 2017 Feb 27; 42(1):93-97. PubMed ID: 27885697
    [Abstract] [Full Text] [Related]

  • 11. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
    Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB.
    Ther Drug Monit; 2008 Dec 27; 30(6):689-99. PubMed ID: 18978522
    [Abstract] [Full Text] [Related]

  • 12. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep 27; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

  • 13. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
    Cvetković M, Zivković M, Bundalo M, Gojković I, Spasojević-Dimitrijeva B, Stanković A, Kostić M.
    Ther Drug Monit; 2017 Dec 27; 39(6):589-595. PubMed ID: 29135906
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D, Wyzgał J, Pączek L.
    Ann Transplant; 2012 Dec 27; 17(3):36-44. PubMed ID: 23018254
    [Abstract] [Full Text] [Related]

  • 16. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.
    Clin Exp Pharmacol Physiol; 2006 Nov 27; 33(11):1093-8. PubMed ID: 17042920
    [Abstract] [Full Text] [Related]

  • 17. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.
    Ther Drug Monit; 2014 Feb 27; 36(1):71-9. PubMed ID: 24061445
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec 27; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 20. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V.
    Pharmacogenomics; 2011 Oct 27; 12(10):1383-96. PubMed ID: 21902502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.